{"id":"gst-hg141","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GST-HG141 functions as a bispecific monoclonal antibody designed to target multiple immune regulatory pathways. By engaging two complementary immune checkpoint molecules, it aims to overcome resistance mechanisms and amplify T-cell activation and proliferation against tumor cells. This dual-targeting approach is intended to improve efficacy compared to single-checkpoint inhibitors.","oneSentence":"GST-HG141 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:39.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07090759","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment","status":"RECRUITING","sponsor":"Fujian Akeylink Biotechnology Co., Ltd.","startDate":"2025-07-24","conditions":"Chronic Hepatitis b","enrollment":526},{"nctId":"NCT05637541","phase":"PHASE2","title":"Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets","status":"COMPLETED","sponsor":"Fujian Akeylink Biotechnology Co., Ltd.","startDate":"2023-01-03","conditions":"Chronic Hepatitis b","enrollment":90},{"nctId":"NCT04868981","phase":"PHASE1","title":"Study on the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets","status":"COMPLETED","sponsor":"Fujian Cosunter Pharmaceutical Co. Ltd","startDate":"2021-05-31","conditions":"Hepatitis B","enrollment":30},{"nctId":"NCT04386915","phase":"PHASE1","title":"Study on the Tolerance and Pharmacokinetics of GST-HG141 Tablets","status":"UNKNOWN","sponsor":"Fujian Cosunter Pharmaceutical Co. Ltd","startDate":"2020-05-18","conditions":"Hepatitis B","enrollment":104}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GST-HG141","genericName":"GST-HG141","companyName":"Fujian Akeylink Biotechnology Co., Ltd.","companyId":"fujian-akeylink-biotechnology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GST-HG141 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}